Schering Corporation

The University of Texas System

Baylor Research Institute

Merck Sharp + Dohme Corp.

Yong-Jun Liu

J Fernando Bazan

Robert A Kastelein

Naoya Tsurushita

J Yun Tso

Rene De Waal Malefyt

Shankar Kumar

Kui Shin Voo

Laura Bover

Vassili Soumelis

Pedro A Reche-Gallardo

Sandra M Zurawski

SangKon Oh

Gerard T Hardiman

Patrick Blanco

Hyemee Joo

Hideki Ueno

Fernando L Rock

Haruyuki Fujita

Shino Hanabuchi

Stephen W K Ho

Vassilli Soumelis

Bianca Blom

Daniel M Gorman

Serge J E Lebecque

Lynette M Dowling

Constance F Huffine

Christopher G Mueller

Marehalli L Nagalakshmi

Wei Yuan

Norihiko Watanabe

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-OX40 antibodies and methods of using the same

Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-&#x3b1; and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell&#x2014;(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

Antagonistic anti-OX40L antibodies and methods of their use

Nucleic acid encoding anti-OX40 antibodies

Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

Antibodies to IL-B50

Anti-OX40 antibodies and methods of treating cancer

Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Method of treatment using an anti-IL-B50 antibody

IL-B50 polypeptide

Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.

Human DNAX toll-like receptor 4 proteins, related reagents and methods

Mammalian cytokines; receptors; related reagents and methods

Human receptor proteins; related reagents and methods

Cytokine receptor

Growing community of inventors

Pearland, TX, United States of America

Yong-Jun Liu